Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France
Off-label prescribing (OLP) may raise serious safety concerns that traditional spontaneous reporting of adverse drug reactions (ADRs) may not identify in a timely manner. In France, the ‘Multidisciplinary Consultation Service for Off-Label Prescribing in Addiction Medicine’ (CAMTEA) is a proactive regional system established to identify ADRs associated with the OLP of baclofen for alcohol dependence.
The aim was to demonstrate, using the French pharmacovigilance database (FPVD), that CAMTEA allowed for the reporting of a substantial amount of ADRs, comparable in nature to those provided via spontaneous reporting.
The 2012–2013 FPVD notifications associated with baclofen OLP were extracted. The ten most frequent types of ADRs among ‘serious’ and ‘non-serious’ reports were listed. The frequency of each type of ADR was compared between CAMTEA and spontaneous reporting, and the magnitudes of the differences were assessed using standardized differences.
A total of 428 baclofen reports (1043 ADRs) were identified, among which 221 (51.64%) originated from CAMTEA. The ten most frequent ADRs in ‘serious’ reports were (1) confusion (17.3%), (2) seizures (11.5%), (3) drowsiness/sedation (11.5%), (4) agitation (10.9%), (5) coma (9.6%), (6) hallucinations (7.7%), (7) falls (7.1%), (8) behavioral disorders (5.8%), (9) withdrawal syndrome (5.1%), and (10) space–time disorientation (5.1%). A standardized difference of <0.2 was identified for six out of the ten most frequent ‘serious’ ADRs, and eight of the ten ‘non-serious’ ADRs.
A proactive regional pharmacovigilance system could collect a substantial amount of safety data on a specific OLP practice. The profile of the ADRs collected was similar to that seen in the nationwide spontaneous reporting system.
- 2.Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;37(476–86):396.Google Scholar
- 4.Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Baclofène: Résumé des Caractéristiques Produit [Baclofen: summary of product characteristics]. 2013. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0232890.htm. Accessed 20 Nov 2016.
- 6.Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Mise en garde sur l’utilisation hors AMM du baclofène dans le traitement de l’alcoolo-dépendance [Cautionary statement regarding the off-label use of baclofen in the treatment of alcohol dependence]. 2011. http://ansm.sante.fr/var/ansm_site/storage/original/application/b88517d4324d10054712c930f22c464b.pdf. Accessed 20 Nov 2016.
- 7.Comité Technique National de Pharmacovigilance. Effets indésirables du baclofène dans le traitement des addictions. Suivi national de pharmacovigilance: année 2011 [Baclofen-related adverse reactions in the treatment of addiction. 2011 national pharmacovigilance monitoring]. http://ansm.sante.fr/content/…/baclofene–suivi-pharmacovigilance-2011.pdf. Accessed 20 Nov 2016.
- 10.Food and Drug Administration. What is a serious adverse event? 2016. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm. Accessed 20 Nov 2016.
- 16.Rolland B, Valin T, Langlois C, Auffret M, Gautier S, Deheul S, et al. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. Int Clin Psychopharmacol. 2015;30:49–53.CrossRefPubMedGoogle Scholar